Research

Hormonal

Adjuvant semaglutide at lower doses (≤1 mg/week) achieves clinically significant weight loss (median 7.5% TWL) in post-bariatric surgery patients with refractory obesity, with a favorable side effect profile compared to higher doses.

If you have had bariatric surgery and are experiencing weight regain or insufficient loss, ask your doctor about adjuvant semaglutide. You may not need the highest dose (2.4 mg); many patients achieve significant weight loss (around 7.5% of total body weight) at lower doses (1 mg or less). This approach is often more affordable, has fewer side effects, and is sufficient for long-term management, especially if supply of higher doses is an issue.

ModerateSupportsMEDIUM confidence
Our study demonstrates that effective weight loss is possible at doses of GLP1a that are lower than previously reported... 78% of the cohort in the current study achieved weight loss at doses of 1.0 mg or less.
J. Ferguson et al. · Obesity Surgery · 2025

Why this rating

Single-center retrospective cohort study; lacks randomization and control group, but has a substantial sample size (n=159).

Source

Effectiveness of Adjuvant Semaglutide Following Bariatric Metabolic Surgery

J. Ferguson et al. · Obesity Surgery · 2025

DOI 10.1007/s11695-025-07703-0

cohort · n=159Cited 9×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →